Article | November 18, 2026

The Hidden Risks Of Novel Capsid Generation (And How To Avoid Them)

Source: Viralgen

By Jacob Smith, Viralgen; Sabrina Triffault, Genosafe; Laurence Jeanson-Leh, GenoSafe; Jacob Staudhammer, Dark Horse Consulting Group; Daniel Lourenco, Dark Horse Consulting Group

GettyImages-597971944-viral-vector-AAV-adeno-associated-virus

Engineering novel capsids through rational design and directed evolution unlocks incredible potential for viral vector applications, yet minor structural alterations frequently trigger unexpected challenges in manufacturing and analytical testing. Sequence similarity to a parent serotype does not guarantee process compatibility; even subtle surface changes can disrupt affinity resin binding, full/empty separation, and host cell protein profiles. Furthermore, quality control strategies often require tailored identity, safety, and potency assays alongside custom positive controls. Integrating capsid selection, manufacturing feasibility, and analytical development from the earliest stages helps mitigate these hidden roadblocks.

Read the full article to discover practical benchmarking strategies and regulatory approaches that safeguard your next-generation viral vector programs.

Access The Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene